has server used (United States) ping response time Hosted in Linode Register Domain Names at Network Solutions, LLC. This domain has been created 15 years, 24 days ago, remaining 340 days. You can check the 8 Websites and blacklist ip address on this server

Domain information

Registrar WHOIS Server:

Registrar URL:     See All 526,027+

Creation Date: 2006-03-24 15 years, 24 days

Updated Date: 2021-01-22 84 days ago

Expiry Date: 2022-03-23 340 days left     See All

  Sign up for notifications near expiration

Registrar: Network Solutions, LLC

Abuse Email: [email protected]

Abuse Phone: +1.8003337680

  Full details

Top 10 Hosting Providers

Registrar URLDomain CountsRegistrar NameAbuse Email,280,, LLC[email protected]
www.tucows.com535,579Tucows Domains Inc.
networksolutions.com526,027Network Solutions, LLC[email protected]
www.namecheap.com333,839NameCheap, Inc.[email protected]
www.enom.com299,925eNom, LLC
www.publicdomainregistry.com294,948PDR Ltd. d/b/a[email protected],, LLC[email protected]
www.fastdomain.com161,753FastDomain Inc.[email protected]
www.ionos.com159,2071&1 IONOS SE[email protected]
www.networksolutions.com149,653Network Solutions, LLC[email protected]

Full view & Download

Keywords Suggestions

  › Amplyx

  › Amplyx pharmaceuticals

  › Amplyx stock

  › Amplyx pharmaceuticals stock

  › Amplyx pharmaceuticals san diego

  › Amplyx therapeutics

  › Amplyx pharmaceuticals ipo

  › Amplyx san diego

See More:   A   B   C   D   E   F   G   H   I   J   K   L   M   N   O   P   Q   R   S   T   U   V   W   X   Y   Z  

› Amplyx pharmaceuticals san diego

› Amplyx pharmaceuticals inc

› Amplyx therapeutics

› Amplyx pharma

› Amplyx pharmaceuticals

› Amplyx rumors

› Amplyx stock

› Amplyx pfizer

Hosting Provider


Organization: Linode     See All 75,628+

Provider URL:


IP Server: Reg: 2015-04-29, Updated: 2015-04-29

Blacklist: Check Backlist Status

Country: United States

Address: 249 Arch St, Philadelphia, PA 19106, US

Latitude: 37.548302

Longitude: -121.988602

Name Server:


Abuse Email: [email protected]

Abuse Phone: +1-609-380-7304

Top 10 Hosting Providers

Website URLDomain CountsOrganizationAbuse Email
Google.com681,421Google LLC[email protected]
Godaddy.com650,, LLC[email protected]
Cloudflare.com637,900Cloudflare, Inc.[email protected]
Endurance.com488,827The Endurance International Group, Inc.[email protected]
Amazon.com439,891Amazon Technologies Inc.[email protected]
297,405Domain Name Services
Amazonaws.com287,121Amazon Technologies Inc.[email protected]
Liquidweb.com159,971Liquid Web, L.L.C[email protected]
Squarespace.com150,667Squarespace, Inc.[email protected]
Ripe.net128,362RIPE Network Coordination Centre[email protected]

Full view & Download

List of found email addresses

  1: [email protected]

  2: [email protected]

  3: [email protected]

  4: [email protected]

  5: [email protected]

Find Websites hosted






6: Changed to:



At least 8 Sites on this server

Port Scanner (IP:

Internet Providers Near Me Toledo NW Ohio Amplex Internet

  • Your search for "Internet service providers near me" has ended! Look no further than Amplex Internet   DA: 14 PA: 14 MOZ Rank: 28

Amplyx Unveils Expanded Pipeline And Reports Phase 2 Data

  • The full press release is available on Amplyx's website.
  • Phase 2 drug candidate for BK viral disease in transplant patients licensed from Novartis
  • Amplyx announced that it has executed an exclusive worldwide license agreement with Novartis under which Amplyx has acquired the rights to the Phase 2 anti-BK virus (BKV) monoclonal antibody, MAU868, for the treatment and prevention of BKV disease.   DA: 18 PA: 50 MOZ Rank: 69

Developing A New Therapeutic For The Treatment Of Invasive

  • Email: [email protected]
  • DESCRIPTION provided by applicant Invasive aspergillosis IA caused by the fungus Aspergillus fumigatus is associated with mortality rates of In response to the lack of effective treatments the Infectious Diseases Society of America highlighted A fumigatus as one of only six   DA: 12 PA: 26 MOZ Rank: 40

Amplyx Closes $53 Million Series C Extension

  • New investors, Pfizer and Adage Capital, bring total Series C financing to over $90 million
  • LONDON, 20 May 2020: Arix Bioscience plc (“Arix”, LSE: ARIX) a global venture capital company focused on investing in and building breakthrough biotech companies, today notes that its portfolio company, Amplyx Pharmaceuticals (“Amplyx”), has announced that it has closed a $53.0 million Series C   DA: 18 PA: 49 MOZ Rank: 70

Amplyx Pharmaceuticals, Inc Company Contact Information

Get Amplyx Pharmaceuticals, Inc company's verified contact number +1*****755, web address, revenue, total contacts 24, industry Healthcare, Pharmaceuticals, & Biotech and location at   DA: 12 PA: 36 MOZ Rank: 52

Amplyx Pharmaceuticals Company Profile: Valuation

  • Amplyx Pharmaceuticals General Information Description
  • Developer of antifungal agents intended to treat invasive fungal infections
  • The company's agents use both intravenous and oral formulations to address the need for treatment in both the hospital setting and continued convenient treatment after discharge from the hospital, enabling patients undergoing chemotherapy and other   DA: 13 PA: 26 MOZ Rank: 44

Mike Hodges’s Email & Phone Amplyx’s Chief Medical Officer

95% Email Accuracy Guarantee Search for people, get full profile information with verified email address and mutual contacts Turn cold outreach into warm introductions by reaching out to people through your network relationships - across various professional and social networks   DA: 16 PA: 30 MOZ Rank: 52

Arix Bioscience Participates In $67 Million Series C

  • Amplyx has completed Phase I clinical trials for both IV and oral formulations of APX001 to address the need for hospital administration as well as continued dosage after hospital discharge
  • Food and Drug Administration (FDA) has granted orphan drug designation to APX001 and has also designated APX001 as a Qualified Infectious Disease   DA: 18 PA: 50 MOZ Rank: 75

Amplyx Pharmaceuticals, Inc LinkedIn

  • Amplyx Pharmaceuticals, Inc | 1,641 followers on LinkedIn
  • Amplyx was founded on a mission to save lives by developing a new class of antifungal medicine that would overcome the severe limitations   DA: 16 PA: 35 MOZ Rank: 59

Amplyx Pharmaceuticals Company Profile

Amplyx Pharmaceuticals is a pharmaceutical company focusing on the development of small molecule drugs, broad-spectrum antifungal agents for the treatment of life-threatening invasive fungal infections due to candida, aspergillus and rare molduls.   DA: 8 PA: 23 MOZ Rank: 40

A Structural Approach For Treating Drug Resistant Fungal

  • DESCRIPTION (provided by applicant): There is an urgent need to discover more effective therapeutic regimens for fungal infections
  • Nosocomial infections caused by Candida albicans have a 50% mortality rate
  • Aspergillosis is a leading cause of death in organ transplant   DA: 12 PA: 25 MOZ Rank: 47

Amplyx To Present New Clinical And Preclinical Data For

  • Amplyx Pharmaceuticals is developing innovative therapies for patients with compromised immune systems, including cancer and transplant patients, and the critically ill   DA: 12 PA: 50 MOZ Rank: 73

Amplyx Doses First Patient In Phase 2 Trial Of APX001 In

  • First Patient has Completed Dosing in Global Phase 2 Clinical Trial for the First-Line Treatment of Patients with Candidemia
  • SAN DIEGO – November 13, 2018 – Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, today announced that the first patient has been dosed in the Company’s Phase 2 clinical program to evaluate the efficacy and   DA: 18 PA: 50 MOZ Rank: 80

Xconomy: Amplyx Inks Novartis Deal For Another Compromised

Amplyx’s experimental drug attacks a fungal enzyme, Gwt1, and in doing so, interrupts the work of a protein that’s essential to the cell wall in fungi, causing damage that leads to cell death.   DA: 11 PA: 50 MOZ Rank: 74

Amplyx Pharmaceuticals Announces Appointment Of CFO And

Amplyx Pharmaceuticals is developing first-in-class products for life-threatening infections, with a near-term focus on deadly fungal pathogens in vulnerable, immune compromised patients.   DA: 18 PA: 50 MOZ Rank: 82

Jobs With Amplyx Pharmaceuticals

  • Amplyx Pharmaceuticals Expands Executive Leadership Team
  • Amplyx Pharmaceuticals , a clinical-stage biopharmaceutical company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune syste
  • Amplyx Pharmaceuticals Advances Development of Novel Antifungal, Fosmanogepix   DA: 16 PA: 40 MOZ Rank: 71

Amplyx To Present New Clinical And Preclinical Data For

  • Top Tickers, 11/17/2020
  • About Amplyx PharmaceuticalsAmplyx Pharmaceuticals is developing innovative therapies for patients with   DA: 21 PA: 50 MOZ Rank: 87

Xconomy: Amplyx Adds Cash From Pfizer, Adage As Funding

Amplyx’s antibody is being tested in Phase 1 studies in kidney transplant recipients with BKV-associated kidney disease and in patients who have received a bone marrow or stem cell transplant   DA: 11 PA: 50 MOZ Rank: 78

Amplyx Pharmaceuticals, Inc Email Format Emails

  • Amplyx Pharmaceuticals, Inc uses 2 email formats, with first_initial last (ex
  • [email protected]) being used 68.8% of the time.
  • Get Verified Emails for Amplyx Pharmaceuticals, Inc Employees   DA: 14 PA: 50 MOZ Rank: 82

Amplyx Pharmaceuticals Expands Executive Leadership Team

Amplyx Pharmaceuticals, a clinical-stage biopharmaceutical company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, today   DA: 17 PA: 50 MOZ Rank: 86

Recently Analyzed

1: 2 seconds ago

2: 1 seconds ago

3: 5 seconds ago

4: 0 seconds ago

5: 2 seconds ago

6: 4 seconds ago

7: 3 seconds ago

8: 1 seconds ago

9: 0 seconds ago

10: 1 seconds ago

Tool Checker

Domain Expiry Date Updated

Expiry DateExpiry DateDomain ProviderHosting Provider 178 days leftTucows Domains Inc.Amazon Technologies Inc. 142 days, LLCGoogle LLC
Dednet.net1 year, 141 days leftNetwork Solutions, LLCNOC4Hosts Inc. 256 days left1&1 IONOS SEDomain Name Services 174 days leftNetwork Solutions, LLCAmazon Technologies Inc.
Acccins.com3 years, 362 days leftNetwork Solutions, LLCAT&T Services, Inc. 311 days, Inc.Cloudflare, Inc. 114 days leftBigRock Solutions LtdGoogle LLC 165 days, LLCAmazon Technologies Inc.
Uniex.com1 year, 78 days, LLC16 COLLYER QUAY

<< See All >>

.COM - 10,595,200+   .ORG - 1,117,549+   .EDU - 123,500+   .NET - 792,945+   .GOV - 30,232+   .US - 84,439+   .CA - 122,904+   .DE - 220,061+   .UK - 272,390+   .IT - 108,882+   .AU - 152,812+   .CO - 51,739+   .BIZ - 59,081+   .IO - 32,494+   .NL - 99,647+   .SG - 19,713+   .INFO - 81,589+   .IE - 26,934+   .ME - 25,076+   .FR - 98,576+   .EU - 61,372+   .RU - 165,043+   .PH - 9,511+   .INT - 1,166+   .IN - 87,021+   .ES - 38,035+   .CZ - 71,869+   .VN - 48,920+   .TV - 14,250+   .SITE - 9,829+   .RO - 37,484+   .PL - 44,520+   .PK - 10,373+   .MOBI - 4,464+   .LK - 5,507+   .CN - 66,137+   .CH - 66,914+   .AT - 31,992+  

Email Address Search | IP Address Blacklist Check | Hosting Providers | Domain Providers | Website Error Checker

© 2018 All rights reserved. Email: [email protected]